Airsculpt Technologies, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 52/100
What the filing says
AirSculpt reported Q2 2026 revenue of $42.9M (−3% YoY) and same-center case growth of 1.0%. The company reduced full-year 2026 Adjusted EBITDA guidance to $12–14M from prior range, while improving liquidity: gross debt fell ~$30M to $44.2M, cash rose ~$10M to $18.8M. On August 7, 2026, the company amended its term loan, extending maturity to November 2027 and requiring $5M prepayment ($2.5M at signing, $2.5M by September 30, 2026), plus 50% of future equity net proceeds toward debt repayment. The company entered an exclusive partnership with AlloClae to offer injectable adipose matrix treatments.
Why this rating
Flat to negative revenue and EBITDA decline (YTD EBITDA $8.2M vs $9.6M) on $79.8M market cap is material. Debt covenant tightening and mandatory prepayments constrain flexibility. Modest case growth (1%) does not offset revenue/margin pressure. Moderate but real business stress.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.